Dynavax Technologies Corporation (NASDAQ:DVAX) – Research analysts at William Blair issued their Q1 2018 EPS estimates for Dynavax Technologies Corporation in a research report issued on Monday. William Blair analyst Y. Xu expects that the biopharmaceutical company will earn ($0.17) per share for the quarter. William Blair has a “Outperform” rating and a $30.00 price objective on the stock. William Blair also issued estimates for Dynavax Technologies Corporation’s Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.02) EPS and Q4 2018 earnings at $0.09 EPS.

A number of other brokerages also recently weighed in on DVAX. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Monday, July 10th. Royal Bank Of Canada set a $7.00 target price on shares of Dynavax Technologies Corporation and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Cowen and Company reiterated an “outperform” rating and set a $45.00 target price on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. J P Morgan Chase & Co upgraded shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $27.00 in a research note on Monday, July 31st. Finally, BidaskClub cut Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Dynavax Technologies Corporation has an average rating of “Buy” and a consensus target price of $25.00.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/brokers-set-expectations-for-dynavax-technologies-corporations-q1-2018-earnings-dvax/1607470.html.

Shares of Dynavax Technologies Corporation (NASDAQ DVAX) traded up 1.4547% during midday trading on Tuesday, reaching $23.5375. The company had a trading volume of 707,499 shares. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $23.68. The firm’s market capitalization is $1.29 billion. The company has a 50 day moving average of $19.16 and a 200 day moving average of $10.91.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.15 million. During the same quarter last year, the firm posted ($0.75) EPS.

Several large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC boosted its holdings in shares of Dynavax Technologies Corporation by 54.5% in the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,700 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Dynavax Technologies Corporation by 16.5% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 1,700 shares during the period. Legal & General Group Plc grew its position in Dynavax Technologies Corporation by 18.5% during the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 1,950 shares during the period. Wall Street Access Asset Management LLC bought a new stake in Dynavax Technologies Corporation during the second quarter valued at approximately $124,000. Finally, CAPROCK Group Inc. bought a new stake in Dynavax Technologies Corporation during the second quarter valued at approximately $134,000. Hedge funds and other institutional investors own 60.20% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History and Estimates for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.